Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Halldin

Showing results (1-10 of 235) with videos related to

Pageof 24
Sort By:
Journal of Clinical Pharmacology|July 17, 2001
Serotonin 5-HT1A receptor imaging in the human brain with positron-emission tomography: coordination and the standardization and dissemination of methodologyC Halldin
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|May 24, 2012
New PET radiopharmaceuticals beyond FDG for brain tumor imagingB Gulyás, C Halldin
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|March 31, 2012
New developments of dopaminergic imaging in Parkinson's diseaseA Varrone, C Halldin
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|March 10, 2012
New developments of dopaminergic imaging in Parkinson's diseaseA Varrone, C Halldin
Current Pharmaceutical Design|January 5, 2002
PET studies with carbon-11 radioligands in neuropsychopharmacological drug developmentC Halldin, B Gulyás, L Farde
Archives of General Psychiatry|October 24, 1997
Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findingsS Nyberg, L Farde, C Halldin
Ernst Schering Research Foundation Workshop|July 14, 2004
PET for drug developmentC Halldin, B Gulyás, L Farde
Journal of the European Academy of Dermatology and Venereology : JEADV|September 14, 2011
Teaching peripheral nerve blocks for the head and neck area to dermatologistsJ Paoli, C Halldin, C Sandberg
Nuclear Medicine and Biology|May 1, 1994
Fluorine-18-labelled NCQ 115, a selective dopamine D-2 receptor ligand. Preparation and positron emission tomographyC Halldin, T Högberg, L Farde
Neuroscience Letters|February 17, 1992
Gpp(NH)p stimulates [3H]raclopride binding to homogenates from human putamen and accumbensH Hall, C Halldin, G Sedvall
Pageof 24

Showing results (1-10 of 235) with videos related to

Sort By:
Pageof 24
Journal of Clinical Pharmacology|July 17, 2001
Serotonin 5-HT1A receptor imaging in the human brain with positron-emission tomography: coordination and the standardization and dissemination of methodologyC Halldin
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|May 24, 2012
New PET radiopharmaceuticals beyond FDG for brain tumor imagingB Gulyás, C Halldin
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|March 31, 2012
New developments of dopaminergic imaging in Parkinson's diseaseA Varrone, C Halldin
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|March 10, 2012
New developments of dopaminergic imaging in Parkinson's diseaseA Varrone, C Halldin
Current Pharmaceutical Design|January 5, 2002
PET studies with carbon-11 radioligands in neuropsychopharmacological drug developmentC Halldin, B Gulyás, L Farde
Archives of General Psychiatry|October 24, 1997
Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findingsS Nyberg, L Farde, C Halldin
Ernst Schering Research Foundation Workshop|July 14, 2004
PET for drug developmentC Halldin, B Gulyás, L Farde
Journal of the European Academy of Dermatology and Venereology : JEADV|September 14, 2011
Teaching peripheral nerve blocks for the head and neck area to dermatologistsJ Paoli, C Halldin, C Sandberg
Nuclear Medicine and Biology|May 1, 1994
Fluorine-18-labelled NCQ 115, a selective dopamine D-2 receptor ligand. Preparation and positron emission tomographyC Halldin, T Högberg, L Farde
Neuroscience Letters|February 17, 1992
Gpp(NH)p stimulates [3H]raclopride binding to homogenates from human putamen and accumbensH Hall, C Halldin, G Sedvall
Pageof 24